Lord, Abbett & Co
PCVX icon

Lord, Abbett & Co’s Vaxcyte PCVX Stock Holding History

Lord, Abbett & Co’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-245,891
Closed -$20.1M – 570
2024
Q4 		$20.1M Sell
245,891
-66,534
-21% -$6.61M 0.06% 325
2024
Q3 		$35.7M Buy
312,425
+66,183
+27% +$5.96M 0.11% 223
2024
Q2 		$18.6M Sell
246,242
-138,121
-36% -$9.4M 0.06% 332
2024
Q1 		$26.3M Sell
384,363
-1,211
-0.3% -$83.9K 0.08% 285
2023
Q4 		$24.2M Buy
+385,574
New +$20M 0.09% 301

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Lord, Abbett & Co's PCVX Position: Q1 2025 in Review

Lord, Abbett & Co sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 245,891 shares — an estimated $20.1M sold.

Lord, Abbett & Co first reported a position in PCVX in Q4 2023 and held it in 5 quarters. The position peaked at $35.7M in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • Lord, Abbett & Co reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 245,891 Vaxcyte shares in Q1 2025, an estimated $20.1M.
  • Lord, Abbett & Co first reported a position in Vaxcyte in Q4 2023 and held it in 5 quarters.
  • Lord, Abbett & Co's Vaxcyte position peaked at $35.7M in Q3 2024.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Lord, Abbett & Co's 13F filing for Q1 2025, filed 13 May 2025.